FEB 27, 2019 06:45 PM PST

Are They Really Killer-T Cells?

WRITTEN BY: Nicholas Breehl

Scientists at the University of Virginia School of Medicine have discovered a defect in immune cells known as "killer T cells" that explains their inability to destroy cancer tumors. The researchers believe that repairing this defect could make the cells much better cancer killers. Further, they predict their discovery could be used within three to five years to help identify patients who will best respond to cancer therapies.

The finding could be a significant boost to the burgeoning field of immunotherapy, which aims to harness the body's immune defenses to defeat cancer. The discovery could also let doctors better predict and assess how well a patient responds to treatment.

"For a long time, the presence of immune cells in cancer has been associated with a better outcome in patients, but it's not been clear why the immune cells haven't been able to control the cancer. What is the cancer doing?" said researcher Timothy Bullock, Ph.D., of the UVA Cancer Center. "This [finding] gives us plenty of opportunities to come in with interventions to invigorate these T cells and level the playing field substantially, so they're much more competitive."

Building Better Cancer Killers

Despite their fearsome moniker, "killer" T cells often become inactive in solid tumors. UVA's new research sheds light on why. Bullock and his team determined that these sluggish soldiers suffer from a dysfunctional enzyme, enolase 1. Without it, they cannot use a vital nutrient, glucose.

"There is a functional defect in this enzyme that is preventing the cells from breaking down glucose and using it in such a way that they can proliferate and become functional," explained researcher Lelisa F. Gemta. "They don't process it well, and that's what we've been digging into: to find out why do these cells take up glucose but fail to break it down."

By ramping up the effectiveness of the enzyme, the researchers believe they can make the killer T cells much better at killing cancer. The sluggish soldiers would become much more formidable fighters.

The researchers also believe that doctors will be able to examine the enzyme to predict how well a patient will respond to treatment. "I think that there is an opportunity to actually use this enzyme as a read-out for the quality of the T cells that are in the tumor, so that when a physician comes in with a clinical trial, we can theoretically analyze how the T cells metabolically compare within the tumor," said Bullock, of UVA's Department of Pathology. "It's almost a biomarker of immune function and fitness within the tumors."

The research is part of UVA's aggressive efforts to advance the field of immunotherapy. For example, it is conducting a leading-edge clinical trial of experimental immunotherapy for pediatric acute lymphoblastic leukemia that has resisted other forms of treatment. The approach, known as chimeric antigen receptor T-cell therapy, takes a child's immune cells and genetically modifies them to make them better at killing cancer.

By confronting the defect, they have discovered and making these T cells fitter, Bullock hopes that his discovery will complement such emerging treatments and make them more effective. The finding, he notes, also might be put to use one day to dampen excessive immune responses, such as are seen in autoimmune disorders.

Sources: Science Daily, Science, YouTube

About the Author
You May Also Like
JAN 22, 2020
Health & Medicine
JAN 22, 2020
Balanced Gut Bacteria May Relieve Anxiety Symptoms
The Anxiety and Depression Association of America estimates that 18% of adults in the United States suffer from an anxiety disorder. According to the World...
JAN 22, 2020
Health & Medicine
JAN 22, 2020
Rare Bone Marrow Manifestation in Sarcoidosis
Sarcoidosis is an inflammatory disease with the hallmark diagnostic feature being non-caseating granulomas--clumps of immune cells including macr...
JAN 22, 2020
Cardiology
JAN 22, 2020
Strep Throat Can Lead To Heart Complications
Rheumatic fever (RF) is a complication resulting from untreated strep throat. Caused by group A streptococcal infection, rheumatic fever was once the numbe...
JAN 22, 2020
Drug Discovery & Development
JAN 22, 2020
Promising Results for New Vaccine Against Dengue Fever
Dengue fever is an illness transmitted by mosquito bites. Affecting around 390 million people per year, if left untreated, its mortality rate is 20%. Altho...
JAN 22, 2020
Drug Discovery & Development
JAN 22, 2020
Drug To Treat Ulcerative Colitis
Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmu...
JAN 22, 2020
Health & Medicine
JAN 22, 2020
A Natural Approach to Pain Management
In many instances, pain can be a rather useful tool. It informs individuals that something is amiss with their body and they should seek treatment. However...
Loading Comments...